帕博利珠单抗在EGFR突变、PD-L1阳性、未接受TKI治疗的晚期NSCLC中的II期研究
该单中心II期试验评估帕博利珠单抗用于未接受TKI治疗的EGFR突变、PD-L1阳性晚期NSCLC患者,计划入组25例,因无效在11例后终止。仅1例(9%)客观缓解且经复核EGFR突变报告有误,另有两例死亡(含1例肺炎),提示该药在此人群无效。
要点
- 帕博利珠单抗在TKI初治EGFR突变PD-L1阳性晚期NSCLC中客观缓解率仅9%(1/11),且该缓解者EGFR突变复核为误报。
- 试验因无效提前终止,仅入组11例(计划25例),两例死亡(含1例肺炎)需关注。
- 结果提示帕博利珠单抗不适合作为该人群的治疗选择,包括PD-L1≥50%者。
核心结论
- 帕博利珠单抗在TKI初治、PD-L1阳性、EGFR突变晚期NSCLC患者中缺乏疗效,包括PD-L1表达≥50%者,提示不适合该人群。
研究设计与样本
- II期试验(NCT02879994),纳入TKI初治、EGFR突变阳性、PD-L1阳性(≥1%,22C3抗体)的晚期NSCLC患者,帕博利珠单抗200 mg每3周一次,主要终点为客观缓解率。
主要发现
- 仅1例(9%)达到客观缓解,但复核该患者肿瘤证实原EGFR突变报告有误。
- 治疗相关不良事件与既往帕博利珠单抗经验相似,但入组6个月内发生两例死亡,其中一例归因于肺炎。
关键数值与推荐
- 客观缓解率仅9%(1/11),且唯一缓解者EGFR突变复核为误报。
- 入组6个月内两例死亡,其中一例归因于肺炎。
临床怎么用
- 对于TKI初治、EGFR突变、PD-L1阳性的晚期NSCLC患者,不应选择帕博利珠单抗治疗,包括PD-L1≥50%者。
局限性
- 试验因无效提前终止,样本量小(仅11例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical benefit has been less frequently observed in patients whose tumors harbor EGFR mutations compared to EGFR wild-type patients. Our single-center experience on the KEYNOTE-001 trial suggested that pembrolizumab-treated EGFR-mutant patients, who were tyrosine kinase inhibitor (TKI) naïve, had superior clinical outcomes to those previously treated with a TKI. As TKI naïve EGFR-mutants have generally been excluded from pembrolizumab studies, data to guide treatment decisions in this patient population is lacking, particularly in patients with programmed death ligand 1 (PD-L1) expression ≥50%. METHODS: We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation-positive, advanced NSCLC and PD-L1-positive (≥1%, 22C3 antibody) tumors. Pembrolizumab was administered 200 mg every 3 weeks. The primary endpoint was objective response rate. Secondary endpoints included safety of pembrolizumab, additional pembrolizumab efficacy endpoints, and efficacy and safety of an EGFR TKI after pembrolizumab. RESULTS: Enrollment was ceased due to lack of efficacy after 11 of 25 planned patients were treated. Eighty-two percent of trial patients were treatment naïve, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression ≥50%. Only 1 patient had an objective response (9%), but repeat analysis of this patient's tumor definitively showed the original report of an EGFR mutation to be erroneous. Observed treatment-related adverse events were similar to prior experience with pembrolizumab, but two deaths within 6 months of enrollment, including one attributed to pneumonitis, were of concern. CONCLUSIONS: Pembrolizumab's lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression ≥50%, suggests that it is not an appropriate therapeutic choice in this setting.
引用
- Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018. PMID: 29874546. doi:10.1016/j.jtho.2018.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。